IRF4 and Miyoshi myopathy: Interferon regulatory factor 4 (IRF4) acts as a lymphocyte-specific transcription factor [30]; it is oncogenic and overexpressed when translocated to actively transcribed genomic regions in some MM patients, but it also has a survival effect in MM in the absence of translocations or amplification [30].